Kyverna Therapeutics, Inc. 8-K

What Happened

• Kyverna Therapeutics (KYTX) filed an 8‑K reporting that Chief Technology Officer Karen Walker notified the company on January 29, 2026 that she will retire and cease serving as CTO effective February 9, 2026. Her resignation is not due to any disagreement with the company.
• The company also announced on February 3, 2026 (press release) that Mayo Pujols will become CTO effective February 9, 2026.
• On January 29, 2026 the Compensation Committee approved an amendment and restatement of the Kyverna Therapeutics 2024 Inducement Equity Incentive Plan to increase the share pool by 1,000,000 shares to an aggregate 5,000,000 shares.

Key Details

• Karen Walker notified the company on Jan 29, 2026; her departure is effective Feb 9, 2026 and not due to any disagreement with the company.
• Mayo Pujols was named CTO, effective Feb 9, 2026 (announced Feb 3, 2026).
• The 2024 Inducement Equity Incentive Plan was amended Jan 29, 2026 to raise available common stock for grants by 1,000,000 shares (new total: 5,000,000 shares).
• The plan amendment was adopted by the Compensation Committee without stockholder approval under Nasdaq Rule 5635(c)(4) and continues to limit awards to individuals granted equity as a material inducement to join (new hires or rehired employees after a bona fide break in employment).

Why It Matters

• Management continuity: Investors should note the CTO transition is planned and immediate (same effective date for resignation and new appointment), and the filing says the departure is not due to any disagreement, which reduces near‑term governance risk.
• Potential dilution and hiring flexibility: Increasing the inducement plan by 1,000,000 shares creates additional equity that can be used to recruit or rehire key technical personnel. That could lead to incremental share grants over time, which may have a modest dilutive effect depending on future awards.
• Governance note: The plan increase was approved by the board committee under Nasdaq rules without a shareholder vote, but remains restricted to use for new or returning employees as an inducement rather than for existing staff or directors.